Bartter syndrome historical perspective: Difference between revisions

Jump to navigation Jump to search
Line 7: Line 7:
*Authors in the paper reported two pediatric patients with growth and developmental delay associated with hypokalemic alkalosis and normal blood pressure despite high aldosterone production.
*Authors in the paper reported two pediatric patients with growth and developmental delay associated with hypokalemic alkalosis and normal blood pressure despite high aldosterone production.
*The syndrome named after Bartter. This disease was observed in children as well as in adults, females as well as males.<ref name="pmid16773399">{{cite journal| author=Proesmans W| title=Threading through the mizmaze of Bartter syndrome. | journal=Pediatr Nephrol | year= 2006 | volume= 21 | issue= 7 | pages= 896-902 | pmid=16773399 | doi=10.1007/s00467-006-0113-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16773399  }} </ref>
*The syndrome named after Bartter. This disease was observed in children as well as in adults, females as well as males.<ref name="pmid16773399">{{cite journal| author=Proesmans W| title=Threading through the mizmaze of Bartter syndrome. | journal=Pediatr Nephrol | year= 2006 | volume= 21 | issue= 7 | pages= 896-902 | pmid=16773399 | doi=10.1007/s00467-006-0113-7 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16773399  }} </ref>
*Authors described in the paper that this disease is characterized by hypokalemia, metabolic alkalosis, hyperreninemia, secondary hyperaldosteronism, and normal blood pressure.
*Hyperrinemia on histopathological examination is characterized by hyperplasia of juxtaglomerular complex.<ref name="pmid13969763">{{cite journal| author=BARTTER FC, PRONOVE P, GILL JR, MACCARDLE RC| title=Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. | journal=Am J Med | year= 1962 | volume= 33 | issue=  | pages= 811-28 | pmid=13969763 | doi=10.1016/0002-9343(62)90214-0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=13969763  }} </ref>
*Fichman <ref name="pmid798488">{{cite journal| author=Fichman MP, Telfer N, Zia P, Speckart P, Golub M, Rude R| title=Role of prostaglandins in the pathogenesis of Bartter's syndrome. | journal=Am J Med | year= 1976 | volume= 60 | issue= 6 | pages= 785-97 | pmid=798488 | doi=10.1016/0002-9343(76)90892-5 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=798488  }} </ref> , Verberckmoes <ref name="urlwww.kidney-international.org">{{cite web |url=https://www.kidney-international.org/article/S0085-2538(15)31580-5/pdf |title=www.kidney-international.org |format= |work= |accessdate=}}</ref>, and Gill <ref name="pmid820194">{{cite journal| author=Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW | display-authors=etal| title=Bartter's syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. | journal=Am J Med | year= 1976 | volume= 61 | issue= 1 | pages= 43-51 | pmid=820194 | doi=10.1016/0002-9343(76)90029-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=820194  }} </ref> in 1976 explained that the production of prostaglandin E2 increases in urine in patients with Bartter syndrome. Later, only the urinary metabolite 6 keto, PGF1, has been measured. Further investigation disclosed that the potent vasodilator PGI2 increases in the blood vessels in Bartter syndrome.<ref name="pmid90861">{{cite journal| author=Güllner HG, Cerletti C, Bartter FC, Smith JB, Gill JR| title=Prostacyclin overproduction in Bartter's syndrome. | journal=Lancet | year= 1979 | volume= 2 | issue= 8146 | pages= 767-9 | pmid=90861 | doi=10.1016/s0140-6736(79)92116-0 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=90861  }} </ref>


==References==
==References==

Revision as of 12:09, 30 July 2020

Bartter syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Bartter syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bartter syndrome historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bartter syndrome historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bartter syndrome historical perspective

CDC on Bartter syndrome historical perspective

Bartter syndrome historical perspective in the news

Blogs on Bartter syndrome historical perspective

Directions to Hospitals Treating Bartter syndrome

Risk calculators and risk factors for Bartter syndrome historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Tayyaba Ali, M.D.[2]

Overview

Historical Perspective

  • Bartter Syndrome was first discovered by Bartter et al.and introduced in a seminal paper in the December issue of the American Journal of Medicine in 1962.
  • Authors in the paper reported two pediatric patients with growth and developmental delay associated with hypokalemic alkalosis and normal blood pressure despite high aldosterone production.
  • The syndrome named after Bartter. This disease was observed in children as well as in adults, females as well as males.[1]
  • Authors described in the paper that this disease is characterized by hypokalemia, metabolic alkalosis, hyperreninemia, secondary hyperaldosteronism, and normal blood pressure.
  • Hyperrinemia on histopathological examination is characterized by hyperplasia of juxtaglomerular complex.[2]
  • Fichman [3] , Verberckmoes [4], and Gill [5] in 1976 explained that the production of prostaglandin E2 increases in urine in patients with Bartter syndrome. Later, only the urinary metabolite 6 keto, PGF1, has been measured. Further investigation disclosed that the potent vasodilator PGI2 increases in the blood vessels in Bartter syndrome.[6]

References

  1. Proesmans W (2006). "Threading through the mizmaze of Bartter syndrome". Pediatr Nephrol. 21 (7): 896–902. doi:10.1007/s00467-006-0113-7. PMID 16773399.
  2. BARTTER FC, PRONOVE P, GILL JR, MACCARDLE RC (1962). "Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome". Am J Med. 33: 811–28. doi:10.1016/0002-9343(62)90214-0. PMID 13969763.
  3. Fichman MP, Telfer N, Zia P, Speckart P, Golub M, Rude R (1976). "Role of prostaglandins in the pathogenesis of Bartter's syndrome". Am J Med. 60 (6): 785–97. doi:10.1016/0002-9343(76)90892-5. PMID 798488.
  4. "www.kidney-international.org".
  5. Gill JR, Frölich JC, Bowden RE, Taylor AA, Keiser HR, Seyberth HW; et al. (1976). "Bartter's syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis". Am J Med. 61 (1): 43–51. doi:10.1016/0002-9343(76)90029-2. PMID 820194.
  6. Güllner HG, Cerletti C, Bartter FC, Smith JB, Gill JR (1979). "Prostacyclin overproduction in Bartter's syndrome". Lancet. 2 (8146): 767–9. doi:10.1016/s0140-6736(79)92116-0. PMID 90861.


Template:WikiDoc Sources